{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:38:50Z","timestamp":1792525130590,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Evidence of treatment strategies in frail patients (i.e. not fit for combination therapies) with unresectable metastatic colorectal cancer (mCRC) is limited to dose-reduced doublet regimens or oral fluoropyrimidines (FP) with bevacizumab. We conducted a systematic review analyzing evidence for oral FPs with epidermal growth factor receptor (EGFR)-directed monoclonal antibodies for patients with\n                      <jats:italic>RAS<\/jats:italic>\n                      wild-type (WT) mCRC across treatment lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed and Cochrane Library for phase II and phase III studies evaluating oral FPs (capecitabine, S-1 or trifluridine\/tipiracil (FTD\/TPI)) plus EGFR-directed monoclonal antibody (panitumumab or cetuximab) in mCRC. Outcomes included efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven publications met inclusion criteria (n\u2009=\u2009262 patients). First-line data was limited to elderly cohorts receiving capecitabine plus cetuximab or panitumumab with a median progression-free survival (PFS)\/median overall survival (OS) of 7.2\/17.1 months (cetuximab) and 7.5\/23.7 months (panitumumab), respectively. In third-line and beyond, median PFS for the combination of FTD\/TPI plus cetuximab or panitumumab ranged from 2.4 (cetuximab) to 5.8 months (panitumumab), and OS from 9.8 (cetuximab) to 14.2 months (panitumumab). S-1 plus cetuximab was associated with a median PFS of 5.5 months and OS of 13.6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While capecitabine should not be used together with anti-EGFR antibodies, FTD\/TPI in combination with an EGFR-directed antibody appears feasible, shows promising activity and manageable toxicity profile in RAS WT mCRC potentially offering an alternative for frail patients; prospective trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06639-x","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:44:58Z","timestamp":1792489498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review"],"prefix":"10.1007","volume":"152","author":[{"given":"Alena Annbalou","family":"Hasenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Stahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"2","key":"6639_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(22)00334-X","volume":"8","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T et al (2023) Trifluridine\u2013tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol 8(2):133\u2013144","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6639_CR24","doi-asserted-by":"crossref","unstructured":"Burtness B et al. (2026) Amivantamab in recurrent\/metastatic head and neck squamous cell cancer after checkpoint inhibitor and chemotherapy: pivotal results from the phase Ib\/II OrigAMI-4 Study. J Clin Oncol. 44:2271\u20132277","DOI":"10.1200\/JCO.2026.44.16_suppl.6008"},{"issue":"6","key":"6639_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","volume":"37","author":"Committee, E.G","year":"2026","unstructured":"Committee, E.G. et al (2026) Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol 37(6):759\u2013776","journal-title":"Ann Oncol"},{"issue":"11","key":"6639_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham D et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077\u20131085","journal-title":"Lancet Oncol"},{"issue":"14","key":"6639_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"EV Cutsem","year":"2009","unstructured":"Cutsem EV et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417","journal-title":"N Engl J Med"},{"issue":"26","key":"6639_CR2","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W et al (2023) Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO Guideline Update. J Clin Oncol 41(26):4293\u20134312","journal-title":"J Clin Oncol"},{"issue":"27","key":"6639_CR19","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"E D\u00edaz-Rubio","year":"2007","unstructured":"D\u00edaz-Rubio E et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25(27):4224\u20134230","journal-title":"J Clin Oncol"},{"issue":"11","key":"6639_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard J-Y et al (2013) Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023\u20131034","journal-title":"N Engl J Med"},{"issue":"3","key":"6639_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ijc.25369","volume":"128","author":"M Ducreux","year":"2011","unstructured":"Ducreux M et al (2011) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128(3):682\u2013690","journal-title":"Int J Cancer"},{"issue":"6","key":"6639_CR18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.ejca.2012.12.011","volume":"49","author":"M Ducreux","year":"2013","unstructured":"Ducreux M et al (2013) Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13\/0503 study). Eur J Cancer 49(6):1236\u20131245","journal-title":"Eur J Cancer"},{"issue":"5","key":"6639_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3322\/caac.21406","volume":"67","author":"CG Ethun","year":"2017","unstructured":"Ethun CG et al (2017) Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. Cancer J Clin 67(5):362\u2013377","journal-title":"Cancer J Clin"},{"issue":"8","key":"6639_CR16","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8):2282\u20132292","journal-title":"J Clin Oncol"},{"issue":"3","key":"6639_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11523-023-00963-9","volume":"18","author":"N Izawa","year":"2023","unstructured":"Izawa N et al (2023) A Phase II trial of trifluridine\/tipiracil in combination with cetuximab rechallenge in patients with RAS wild-type mCRC refractory to prior anti-EGFR antibodies: WJOG8916G Trial. Target Oncol 18(3):369\u2013381","journal-title":"Target Oncol"},{"issue":"7","key":"6639_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10147-021-01902-2","volume":"26","author":"T Kato","year":"2021","unstructured":"Kato T et al (2021) Safety and efficacy of panitumumab in combination with trifluridine\/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1\/2 APOLLON study. Int J Clin Oncol 26(7):1238\u20131247","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"6639_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgo.2018.11.011","volume":"10","author":"DL Kienle","year":"2019","unstructured":"Kienle DL et al (2019) Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41\/10. J Geriatr Oncol 10(2):304\u2013310","journal-title":"J Geriatr Oncol"},{"issue":"34","key":"6639_CR6","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1200\/JCO.23.00506","volume":"41","author":"S Lonardi","year":"2023","unstructured":"Lonardi S et al (2023) Initial panitumumab plus fluorouracil, leucovorin, and oxaliplatin or plus fluorouracil and leucovorin in elderly patients With RAS and BRAF wild-type metastatic colorectal cancer: the PANDA trial by the GONO foundation. J Clin Oncol 41(34):5263\u20135273","journal-title":"J Clin Oncol"},{"issue":"9783","key":"6639_CR21","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","volume":"377","author":"TS Maughan","year":"2011","unstructured":"Maughan TS et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103\u20132114","journal-title":"Lancet"},{"issue":"8","key":"6639_CR8","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jgo.2020.06.003","volume":"11","author":"JC M\u00e9ndez M\u00e9ndez","year":"2020","unstructured":"M\u00e9ndez M\u00e9ndez JC et al (2020) First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study. J Geriatr Oncol 11(8):1263\u20131267","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"6639_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jamaoncol.2023.0655","volume":"9","author":"S Napolitano","year":"2023","unstructured":"Napolitano S et al (2023) Panitumumab plus trifluridine-tipiracil as anti\u2013epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol 9(7):966\u2013970","journal-title":"JAMA Oncol"},{"issue":"8","key":"6639_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ijc.34632","volume":"153","author":"S Napolitano","year":"2023","unstructured":"Napolitano S et al (2023) Panitumumab plus trifluridine\/tipiracil as anti-EGFR rechallenge therapy in patients with refractory wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. Int J Cancer 153(8):1520\u20131528","journal-title":"Int J Cancer"},{"issue":"17","key":"6639_CR23","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO-25-02187","volume":"44","author":"PE Oberstein","year":"2026","unstructured":"Oberstein PE et al (2026) Amivantamab monotherapy in chemorefractory RAS\/BRAF wild-type metastatic colorectal cancer: results From OrigAMI-1, an Open-Label, Phase Ib\/II Study. J Clin Oncol 44(17):1624\u20131634","journal-title":"J Clin Oncol"},{"issue":"9779","key":"6639_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","volume":"377","author":"MT Seymour","year":"2011","unstructured":"Seymour MT et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377(9779):1749\u20131759","journal-title":"Lancet"},{"issue":"3","key":"6639_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00280-016-3109-4","volume":"78","author":"T Takahashi","year":"2016","unstructured":"Takahashi T et al (2016) Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). Cancer Chemother Pharmacol 78(3):585\u2013593","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"6639_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.annonc.2020.05.024","volume":"31","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E et al (2020) Trifluridine\/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol 31(9):1160\u20131168","journal-title":"Ann Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06639-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06639-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06639-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:46:43Z","timestamp":1792522003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06639-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6639"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06639-x","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"199"}}